Dossier
U.S. launch
Coverage of U.S. launch in the Nexus archive.
- Abivax $920 million cash haul lets it prepare for solo U.S. launch instead of relying on a buyer, CEO tells CNBC
Abivax secured $920 million in funding, enabling the French biotech company to prepare for an independent U.S. launch without relying on a buyer. The funds will cover operations through 2029.
- Polymarket's annualized revenue topped $1 billion within six weeks of its U.S. launch
Polymarket's annualized revenue exceeded $1 billion within six weeks of its U.S. launch. Daily trading volume on the platform increased from approximately $50 million in mid-May to over $200 million by June 20.